Showing 2571-2580 of 5646 results for "".
- Ocugen Granted FDA Orphan Drug Designation for Gene Therapy for the Treatment of RHO Mutation-Associated Retinal Degenerative Diseasehttps://modernod.com/news/ocugen-granted-fda-orphan-drug-designation-for-gene-therapy-for-the-treatment-of-rho-mutation-associated-retinal-degenerative-disease/2478081/Ocugen announced the FDA granted the third orphan drug designation (ODD) for OCU400 in the treatment of RHO mutation-associated retinal degeneration. The RHO mutation is part of the retinitis pigmentosa (RP) group of rare, genetic disorders that involve a breakdown and loss of
- Researchers Capture Cell-Level Details of Curved Corneahttps://modernod.com/news/researchers-capture-cell-level-details-of-curved-cornea/2478069/Researchers have, for the first time, acquired optical coherence tomography (OCT) images of the curved layers of a person’s cornea with cell-level detail and a large viewing area, according to a study in Optica. The new OCT instrument enables improved monitoring of eye diseases as well a
- Phase 3 Data Show Port Delivery System With Ranibizumab Enabled Over 98% of Patients to Go 6 Months Between Treatments for Wet AMDhttps://modernod.com/news/phase-3-data-show-port-delivery-system-with-ranibizumab-enabled-over-98-of-patients-to-go-6-months-between-treatments-for-wet-amd/2478061/Genentech announced detailed results from the phase 3 Archway study evaluating its investigational Port Delivery System with ranibizumab (PDS) for the treatment of wet age-related macular degeneration (AMD). In Archway, 98.4% of PDS patients were able to go 6 months without needing additio
- AGTC Announces Updated Development Plan for its X-Linked Retinitis Pigmentosa Clinical Programhttps://modernod.com/news/agtc-announces-updated-development-plan-for-its-x-linked-retinitis-pigmentosa-clinical-program/2478058/Applied Genetic Technologies Corporation announced next steps in the clinical development of the company’s potential treatment of X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene following receipt of written feedback from the FDA. The revised development p
- Synairgen’s Inhaled Interferon Beta Cuts Chance of Developing Severe COVID-19 Diseasehttps://modernod.com/news/synairgens-inhaled-interferon-beta-cuts-chance-of-developing-severe-covid-19-disease/2478043/Synairgen announced Monday that its inhaled formulation of interferon beta, dubbed SNG001, significantly reduced the chance of developing severe disease compared to placebo in hospitalized COVID-19 patients. Chief study investigator Tom Wilkinson remarked “the results confirm our belief tha
- Appeals Court Rules HHS Has Authority to Implement Site Neutral Payments, Dealing Blow to Hospitalshttps://modernod.com/news/appeals-court-rules-hhs-has-authority-to-implement-site-neutral-payments-dealing-blow-to-hospitals/2478041/A federal appeals court ruled Health and Human Services has the authority to cut Medicare payments to off-campus clinics to bring them in line with independent physician practices, reversing a lower court’s decision, according to a FierceHealthcare
- Novartis to Provide 15 Drugs at Zero-Profit for Treating COVID-19 Symptomshttps://modernod.com/news/novartis-to-provide-15-drugs-at-zero-profit-for-treating-covid-19-symptoms/2478027/Novartis announced Thursday that 15 generic and over-the-counter medicines from its Sandoz unit will be made available at zero-profit to treat the major symptoms of COVID-19 in low-income and lower-middle-income countries. The drugs include those to treat gastro-intestinal illness, acute respirat
- Senate Democrats Demand $25 Billion for Widespread COVID-19 Vaccine Distributionhttps://modernod.com/news/senate-democrats-demand-25-billion-for-widespread-covid-19-vaccine-distribution/2478013/Senate Democrats want to pass legislation that provides $25 billion to ensure a potential COVID-19 vaccine is heavily distributed among the U.S. population, according to a FierceHealthcare
- Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-Specific Antibody Therapeutics for Cancer and Retinal Diseaseshttps://modernod.com/news/numab-therapeutics-and-boehringer-ingelheim-enter-into-collaboration-to-develop-multi-specific-antibody-therapeutics-for-cancer-and-retinal-diseases/2478000/Boehringer Ingelheim and Numab Therapeutics announced that they have entered into a research collaboration and worldwide licensing agreement. It will start with two projects aiming at novel therapies for difficult-to-treat lung and gastrointestinal (GI) cancers and patients with geographic
- EPA Approves Two Lysol Products as the First to Effectively Kill Novel Coronavirus on Surfaceshttps://modernod.com/news/epa-approves-two-lysol-products-as-the-first-to-effectively-kill-novel-coronavirus-on-surfaces/2477986/The US Environmental Protection Agency has approved two Lysol products as effective against the novel coronavirus when used on hard, non-porous surfaces, according to a CNN